CoChat

Context-dependent switch in chemo/mechanotransduction via multilevel crosstalk among cytoskeleton-regulated MRTF and TAZ and TGFβ-regulated Smad3

Open access
Speight, Pam, Kofler, Michael, Szászi, Katalin, Kapus, András · 2016 · Nature Communications

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Myocardin-related transcription factor (MRTF) and TAZ are major mechanosensitive transcriptional co-activators that link cytoskeleton organization to gene expression. Despite many similarities in their regulation, their physical and/or functional interactions are unknown. Here we show that MRTF and TAZ associate partly through a WW domain-dependent mechanism, and exhibit multilevel crosstalk affecting each other’s expression, transport and transcriptional activity. Specifically, MRTF is essential for TAZ expression; TAZ and MRTF inhibit each other’s cytosolic mobility and stimulus-induced nuclear accumulation; they antagonize each other’s stimulatory effect on the α-smooth muscle actin (SMA) promoter, which harbours nearby cis-elements for both, but synergize on isolated TEAD-elements. Importantly, TAZ confers Smad3 sensitivity to the SMA promoter. Thus, TAZ is a context-dependent switch during mechanical versus mechano/chemical signalling, which inhibits stretch-induced but is indispensable for stretch+TGFβ-induced SMA expression. Crosstalk between these cytoskeleton-regulated factors seems critical for fine-tuning mechanical and mechanochemical transcriptional programmes underlying myofibroblast transition, wound healing and fibrogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms11642

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MRTF and TAZ interact partially through the MRTF C terminus and the TAZ WW domain. (a) LLC-PK1 cells were incubated under low-calcium conditions (LCM) for the indicated times. Immunoprecipitation (IP) with anti-MRTF reveals that endogenous TAZ specifically co-precipitates with MRTF. (IgG denotes isotope-matched nonspecific antibody.). (b) Lysates from cells transfected with Myc-MRTF, HA-TAZ or a combination of both were left untreated or exposed to LCM for 30 min and subjected to IP with anti-Myc. HA-TAZ associates specifically with Myc-MRTF. (c) Schematic representation of single or double point mutations in the full-length or truncated proteins used in the study. (d) Western blot analysis following co-IP of HA-TAZ with either full-length WT MRTF or YG MRTF. Note that YG MRTF exhibits significantly reduced TAZ binding. Co-precipitating HA-TAZ was normalized to precipitated MRTF and total HA-TAZ expression. Error bars are ±s.e.m.; **P<0.01; Student's t-test. (e) The N terminus (NT), C terminus (CT) or the C terminus YG mutant (CT/YG) of Myc-MRTF was co-transfected with WT HA-TAZ and their interaction was analysed by co-IP with anti-Myc. Note the strong association of TAZ with the MRTF CT and the loss of association with CT/YG. (f) HA-tagged WT or WW mutant TAZ (WP/AA) was co-transfected with MRTF CT, as indicated. Lysates were precipitated with anti-Myc or isotype-matched control antibody (IgG) and probed for the indicated proteins. All immunoblots (a,b,d–f) are representative of n=3 independent experiments.
Figure 1 MRTF and TAZ interact partially through the MRTF C terminus and the TAZ WW domain. (a) LLC-PK1 cells were incubated under low-calcium conditions (LCM) for the indicated times. Immunoprecipitation (IP) with anti-MRTF reveals that endogenous TAZ specifically co-precipitates with MRTF. (IgG denotes isotope-matched nonspecific antibody.). (b) Lysates from cells transfected with Myc-MRTF, HA-TAZ or a combination of both were left untreated or exposed to LCM for 30 min and subjected to IP with anti-Myc. HA-TAZ associates specifically with Myc-MRTF. (c) Schematic representation of single or double point mutations in the full-length or truncated proteins used in the study. (d) Western blot analysis following co-IP of HA-TAZ with either full-length WT MRTF or YG MRTF. Note that YG MRTF exhibits significantly reduced TAZ binding. Co-precipitating HA-TAZ was normalized to precipitated MRTF and total HA-TAZ expression. Error bars are ±s.e.m.; **P<0.01; Student's t-test. (e) The N terminus (NT), C terminus (CT) or the C terminus YG mutant (CT/YG) of Myc-MRTF was co-transfected with WT HA-TAZ and their interaction was analysed by co-IP with anti-Myc. Note the strong association of TAZ with the MRTF CT and the loss of association with CT/YG. (f) HA-tagged WT or WW mutant TAZ (WP/AA) was co-transfected with MRTF CT, as indicated. Lysates were precipitated with anti-Myc or isotype-matched control antibody (IgG) and probed for the indicated proteins. All immunoblots (a,b,d–f) are representative of n=3 independent experiments.CC BY · PubMed Central
Figure 2 Nuclear translocation of MRTF and TAZ are not directly coupled. (a) LLC-PK1 cells were transfected with FLAG-tagged MRTF or HA-tagged TAZ constructs. The distribution of the tagged proteins in the nuclear and cytosolic compartments was analysed by cell fractionation followed by western blotting. Representative blots are shown for n=4 experiments. (b) Cells plated on glass coverslips were transfected with FLAG-tagged RA MRTF and stained with anti-FLAG and anti-TAZ. Scale bar, 10 μm. The percentage of cells with nuclear TAZ was quantified in nuclear RA expressors (black column) and in untransfected cells (open column) as endogenous control on the same coverslips (at least 100 cells per condition in n=4 experiments; error bars, ±s.e.m.) (RA MRTF was nuclear in 93% of the cells, see Supplementary Fig. 1). The white arrow indicates a cell counted as positive for both nuclear MRTF and TAZ, whereas the black arrow denotes a cell counted as positive for nuclear MRTF but negative for nuclear TAZ. (c) Association profile of WT and mutant MRTF and TAZ constructs. Cells were transfected with FLAG-tagged WT (cytosolic) or RA (fully nuclear) or LL/AA (predominantly nuclear) MRTF constructs along with WT or active (SA, largely nuclear) HA-TAZ. After immunoprecipitation (IP) with anti-HA the precipitates and total lysates were probed for the indicated proteins (n=3). (d) Immunofluorescence analysis of MRTF and TAZ after confluent cells were treated with LCM or 0.5 μM JK for 30 min (n=5; scale bar, 10 μm). (e) JK disrupts the association of MRTF and TAZ. Cells were exposed to vehicle or 0.5 μM JK for 30 min and lysed. The resulting lysates were immunoprecipitated with anti-MRTF antibody, and the precipitates were probed for MRTF and TAZ (n=3).
Figure 2 Nuclear translocation of MRTF and TAZ are not directly coupled. (a) LLC-PK1 cells were transfected with FLAG-tagged MRTF or HA-tagged TAZ constructs. The distribution of the tagged proteins in the nuclear and cytosolic compartments was analysed by cell fractionation followed by western blotting. Representative blots are shown for n=4 experiments. (b) Cells plated on glass coverslips were transfected with FLAG-tagged RA MRTF and stained with anti-FLAG and anti-TAZ. Scale bar, 10 μm. The percentage of cells with nuclear TAZ was quantified in nuclear RA expressors (black column) and in untransfected cells (open column) as endogenous control on the same coverslips (at least 100 cells per condition in n=4 experiments; error bars, ±s.e.m.) (RA MRTF was nuclear in 93% of the cells, see Supplementary Fig. 1). The white arrow indicates a cell counted as positive for both nuclear MRTF and TAZ, whereas the black arrow denotes a cell counted as positive for nuclear MRTF but negative for nuclear TAZ. (c) Association profile of WT and mutant MRTF and TAZ constructs. Cells were transfected with FLAG-tagged WT (cytosolic) or RA (fully nuclear) or LL/AA (predominantly nuclear) MRTF constructs along with WT or active (SA, largely nuclear) HA-TAZ. After immunoprecipitation (IP) with anti-HA the precipitates and total lysates were probed for the indicated proteins (n=3). (d) Immunofluorescence analysis of MRTF and TAZ after confluent cells were treated with LCM or 0.5 μM JK for 30 min (n=5; scale bar, 10 μm). (e) JK disrupts the association of MRTF and TAZ. Cells were exposed to vehicle or 0.5 μM JK for 30 min and lysed. The resulting lysates were immunoprecipitated with anti-MRTF antibody, and the precipitates were probed for MRTF and TAZ (n=3).CC BY · PubMed Central
Figure 3 MRTF downregulation potentiates stimulus-induced nuclear accumulation of TAZ in a WW-binding domain-dependent manner. (a,b) Cells transfected with NR or TAZ siRNA for 48 h were exposed to LCM treatment for the indicated times, stained for MRTF and 4,6-diamidino-2-phenylindole (DAPI), and the percentage of cells with nuclear MRTF was determined (200 cells per condition; n=3; scale bar, 10 μm). (Inset) Verification of TAZ silencing by western blot. (c,d) Nuclear extracts were prepared from cells transfected and treated as in a and probed with anti-MRTF and anti-TAZ. Equal loading was verified using anti-histone antibody. Nuclear MRTF was quantified by densitometry, normalized to histones and total MRTF levels, and expressed as fold change compared with the untreated control (n=3). (e) Cells were co-transfected with Myc-MRTF (WT or YG) and either NR or TAZ siRNA. Following LCM treatment (30 min) the localization of the MRTF constructs was examined using anti-MRTF antibody (n=4). Scale bar, 10 μm (f) Percentage of cells with nuclear MRTF under conditions shown in e. For b,d and f error bars denote ±s.e.m.; ***P<0.001, NS, not significant.
Figure 3 MRTF downregulation potentiates stimulus-induced nuclear accumulation of TAZ in a WW-binding domain-dependent manner. (a,b) Cells transfected with NR or TAZ siRNA for 48 h were exposed to LCM treatment for the indicated times, stained for MRTF and 4,6-diamidino-2-phenylindole (DAPI), and the percentage of cells with nuclear MRTF was determined (200 cells per condition; n=3; scale bar, 10 μm). (Inset) Verification of TAZ silencing by western blot. (c,d) Nuclear extracts were prepared from cells transfected and treated as in a and probed with anti-MRTF and anti-TAZ. Equal loading was verified using anti-histone antibody. Nuclear MRTF was quantified by densitometry, normalized to histones and total MRTF levels, and expressed as fold change compared with the untreated control (n=3). (e) Cells were co-transfected with Myc-MRTF (WT or YG) and either NR or TAZ siRNA. Following LCM treatment (30 min) the localization of the MRTF constructs was examined using anti-MRTF antibody (n=4). Scale bar, 10 μm (f) Percentage of cells with nuclear MRTF under conditions shown in e. For b,d and f error bars denote ±s.e.m.; ***P<0.001, NS, not significant.CC BY · PubMed Central
Figure 4 MRTF regulates TAZ expression and localization. (a) Cells transfected with NR or specific siRNAs for 48 h were analysed by immunoblotting for expression of the indicated proteins. (b) The effect of MRTF silencing on TAZ mRNA levels (n=3). (c) Enhanced actin polymerization increases TAZ expression. Confluent monolayers were treated with 0.5 μM JK for the indicated times and TAZ protein expression was determined by western blotting. (d) Cells were treated with JK as indicated and analysed for TAZ mRNA. (e) Cells co-transfected for 48 h with HA-TAZ and NR or MRTF siRNA were doubly stained for HA and MRTF (left panel). Percentage of cells with nuclear HA-TAZ was quantified (right panel). Scale bar, 10 μm. (f) Immunofluorescence analysis of cells transfected with NR or MRTF siRNA, followed by treatment with LCM for the indicated times. The percentage of cells showing nuclear TAZ accumulation was plotted as a function of the treatment time. (g) MRTF was silenced as in e and the expression of 14-3-3 proteins was determined by western blotting and quantified by densitometry. Western blots (a,c,g) were repeated a minimum of three times. Error bars in b,d,f,e and g represent ±s.e.m.; *P<0.05; **P<0.01; ***P<0.001 by Student's t-test or one-way analysis of variance.
Figure 4 MRTF regulates TAZ expression and localization. (a) Cells transfected with NR or specific siRNAs for 48 h were analysed by immunoblotting for expression of the indicated proteins. (b) The effect of MRTF silencing on TAZ mRNA levels (n=3). (c) Enhanced actin polymerization increases TAZ expression. Confluent monolayers were treated with 0.5 μM JK for the indicated times and TAZ protein expression was determined by western blotting. (d) Cells were treated with JK as indicated and analysed for TAZ mRNA. (e) Cells co-transfected for 48 h with HA-TAZ and NR or MRTF siRNA were doubly stained for HA and MRTF (left panel). Percentage of cells with nuclear HA-TAZ was quantified (right panel). Scale bar, 10 μm. (f) Immunofluorescence analysis of cells transfected with NR or MRTF siRNA, followed by treatment with LCM for the indicated times. The percentage of cells showing nuclear TAZ accumulation was plotted as a function of the treatment time. (g) MRTF was silenced as in e and the expression of 14-3-3 proteins was determined by western blotting and quantified by densitometry. Western blots (a,c,g) were repeated a minimum of three times. Error bars in b,d,f,e and g represent ±s.e.m.; *P<0.05; **P<0.01; ***P<0.001 by Student's t-test or one-way analysis of variance.CC BY · PubMed Central
Figure 5 TAZ and MRTF mutually inhibit each other's cytosolic mobility. (a) Cells were co-transfected with GFP-MRTF and NR or TAZ siRNA, and FRAP experiments were performed on the cytosolic GFP-MRTF pool (representative images). Bleached regions of interest are circled. (b) Recovery curves (+/−s.d.) and the corresponding curve fitting. Data were normalized to the pre-bleach fluorescence levels. The bar diagram shows the halftime of recovery (n=15 per condition). (c) Cells were co-transfected with GFP-TAZ and NR or MRTF siRNA, and FRAP experiments were performed on the cytosolic GFP-TAZ pool (representative images). (d) Analysis was performed as in b (n=15 per condition). Error bars represent ±s.e.m.; **P<0.01; ***P<0.001; scale bar, 10 μm.
Figure 5 TAZ and MRTF mutually inhibit each other's cytosolic mobility. (a) Cells were co-transfected with GFP-MRTF and NR or TAZ siRNA, and FRAP experiments were performed on the cytosolic GFP-MRTF pool (representative images). Bleached regions of interest are circled. (b) Recovery curves (+/−s.d.) and the corresponding curve fitting. Data were normalized to the pre-bleach fluorescence levels. The bar diagram shows the halftime of recovery (n=15 per condition). (c) Cells were co-transfected with GFP-TAZ and NR or MRTF siRNA, and FRAP experiments were performed on the cytosolic GFP-TAZ pool (representative images). (d) Analysis was performed as in b (n=15 per condition). Error bars represent ±s.e.m.; **P<0.01; ***P<0.001; scale bar, 10 μm.CC BY · PubMed Central
Figure 6 Transcriptional interactions between MRTF and TAZ on WT and mutant SMA promoters. (a) WT and mutant SMA promoter luciferase constructs used in this study. (b) Cells were co-transfected with WT or CArGmut promoter firefly luciferase construct and renilla-TK reporter along with either empty vector control (pcDNA) or the indicated expression plasmids. In all subsequent experiments luciferase activities were determined 24 h post transfection and firefly/renilla ratios were normalized to the pcDNA control. (c) NR or MRTF siRNA were transfected along with WT SMA promoter and pcDNA or SA HA-TAZ expression plasmid. (d) The WT or TBEmut SMA promoter was co-transfected with the indicated plasmids. (e) Titration of the effect of MRTF (0.5 μg) on TBEmut promoter using increasing doses (0–1.5 μg) of TAZ. (f,g) WW-binding domain interactions are important for the TAZ-induced inhibition of MRTF-mediated SMA promoter activation. The WT SMA promoter was transfected with full-length WT or YG MRTF (f) or CT and CT/YG MRTF (g) without or with SA TAZ. (h) Cells were co-transfected with the WT SMA promoter along with NR, TAZ or MRTF siRNA, followed by exposure to control or LCM media. (i) Cells were transfected with NR or TAZ siRNA (siTAZ #2) then incubated in control or LCM media for 24 h. Subsequently, ChIP was performed using anti-MRTF antibody and the abundance of the endogenous SMA promoter in the precipitated DNA was determined by qPCR (n=3). All luciferase assays (b–h) were performed a minimum of three times. Error bars (b–i) are ±s.e.m.; *P<0.05, ***P<0.001 and ****P<0.0001 derived by one-way analysis of variance.
Figure 6 Transcriptional interactions between MRTF and TAZ on WT and mutant SMA promoters. (a) WT and mutant SMA promoter luciferase constructs used in this study. (b) Cells were co-transfected with WT or CArGmut promoter firefly luciferase construct and renilla-TK reporter along with either empty vector control (pcDNA) or the indicated expression plasmids. In all subsequent experiments luciferase activities were determined 24 h post transfection and firefly/renilla ratios were normalized to the pcDNA control. (c) NR or MRTF siRNA were transfected along with WT SMA promoter and pcDNA or SA HA-TAZ expression plasmid. (d) The WT or TBEmut SMA promoter was co-transfected with the indicated plasmids. (e) Titration of the effect of MRTF (0.5 μg) on TBEmut promoter using increasing doses (0–1.5 μg) of TAZ. (f,g) WW-binding domain interactions are important for the TAZ-induced inhibition of MRTF-mediated SMA promoter activation. The WT SMA promoter was transfected with full-length WT or YG MRTF (f) or CT and CT/YG MRTF (g) without or with SA TAZ. (h) Cells were co-transfected with the WT SMA promoter along with NR, TAZ or MRTF siRNA, followed by exposure to control or LCM media. (i) Cells were transfected with NR or TAZ siRNA (siTAZ #2) then incubated in control or LCM media for 24 h. Subsequently, ChIP was performed using anti-MRTF antibody and the abundance of the endogenous SMA promoter in the precipitated DNA was determined by qPCR (n=3). All luciferase assays (b–h) were performed a minimum of three times. Error bars (b–i) are ±s.e.m.; *P<0.05, ***P<0.001 and ****P<0.0001 derived by one-way analysis of variance.CC BY · PubMed Central
Figure 7 TAZ confers Smad3 sensitivity to the SMA promoter. (a) Cells were transfected with the WT SMA promoter and increasing concentrations of Smad3 alone or along with a constant amount (0.5 μg) of SA TAZ (n=3). (b) A varying dose of Smad3 was co-transfected with the SBE4-luc reporter construct (n=3). (c) SBE but not TBE is critical for the Smad3 sensitivity of the SMA promoter. Luciferase activity was measured in cells co-transfected with the indicated promoter constructs and expression plasmids. Data were normalized to the activity of WT SMA promoter in empty vector-transfected cells (n=5). (d) Cells were transfected with the WT SMA promoter and either empty plasmid (pcDNA) or SA TAZ. Following treatment with or without TGFβ, luciferase activity was measured (n=3). (e) The WT or CArG A/B_TBE1/2mut SMA promoter construct was transfected with Smad3 (0.5 or 1 μg, as indicated), SA TAZ (0.5 μg) or a combination of these, and luciferase activity was determined (n=3). (f) SA TAZ overexpression enables TGFβ to induce SMA expression. Cells were transfected with control vector or HA-tagged SA TAZ for 24 h and then left untreated or exposed to TGFβ, as indicated, for an additional 48 h. Western blotting was then performed for the indicated proteins (n=3). (a–e) Error bars represent ±s.e.m.; ****P<0.0001; NS, not significant using one-way analysis of variance.
Figure 7 TAZ confers Smad3 sensitivity to the SMA promoter. (a) Cells were transfected with the WT SMA promoter and increasing concentrations of Smad3 alone or along with a constant amount (0.5 μg) of SA TAZ (n=3). (b) A varying dose of Smad3 was co-transfected with the SBE4-luc reporter construct (n=3). (c) SBE but not TBE is critical for the Smad3 sensitivity of the SMA promoter. Luciferase activity was measured in cells co-transfected with the indicated promoter constructs and expression plasmids. Data were normalized to the activity of WT SMA promoter in empty vector-transfected cells (n=5). (d) Cells were transfected with the WT SMA promoter and either empty plasmid (pcDNA) or SA TAZ. Following treatment with or without TGFβ, luciferase activity was measured (n=3). (e) The WT or CArG A/B_TBE1/2mut SMA promoter construct was transfected with Smad3 (0.5 or 1 μg, as indicated), SA TAZ (0.5 μg) or a combination of these, and luciferase activity was determined (n=3). (f) SA TAZ overexpression enables TGFβ to induce SMA expression. Cells were transfected with control vector or HA-tagged SA TAZ for 24 h and then left untreated or exposed to TGFβ, as indicated, for an additional 48 h. Western blotting was then performed for the indicated proteins (n=3). (a–e) Error bars represent ±s.e.m.; ****P<0.0001; NS, not significant using one-way analysis of variance.CC BY · PubMed Central
Figure 8 Context-dependent switch in mechanical versus mechano/chemical signalling assigns opposite role for TAZ under mechanical (single) versus mechanical+chemical (double) stimulation. (a–e) Single or double stimulation in the context of LCM-induced cell contact disassembly −/+TGFβ treatment (a) TAZ downregulation enables LCM to induce SMA expression. Cells were transfected with NR, TAZ-specific (#1) or YAP-specific siRNA for 24 h and then exposed to control or LCM medium for an additional 48 h. Cell lysates were probed for SMA and the other indicated proteins. (b) MRTF is required for the expression of SMA on TAZ downregulation and LCM treatment. Cells were transfected with NR or specific siRNAs against TAZ (#2), MRTF or their combination, and treated and analysed for the indicated proteins as in a. (c) TAZ downregulation (siTAZ #2) inhibits two-hit (LCM+TGFβ)-induced SMA protein expression. Cells were transfected with NR or TAZ siRNA followed by 48 h treatment with LCM, TGFβ or the combination. Cell lysates were subjected to western blot analysis for the indicated proteins. (d) Cells were co-transfected with the WT SMA promoter and either NR or TAZ siRNA (siTAZ #2). Luciferase activity was measured following treatment with control or LCM+TGFβ (n=3). (e) Confluent monolayers were treated with LCM or LCM+TGFβ for 24 h. ChIP analysis was performed using anti-TAZ or the relevant IgG control and primers for the SMA promoter (n=3). (f–h) Single or double stimulation in the context of stretch −/+TGFβ treatment. TAZ differentially regulates SMA expression on stimulation by stretch or by stretch and TGFβ. Cells grown on Flexcell membranes were transfected with NR or TAZ siRNA (siTAZ #1), treated without or with TGFβ and then further exposed to non-stretch or cyclic stretch conditions (10% stretch at 1 Hz for 6 h). (f) Cell lysates were prepared and analysed by western blotting for the indicated proteins. (g) The graph depicts the quantitation of SMA expression under stretch conditions. Data are expressed as fold change compared with the level of stretch+TGFβ-induced SMA expression. (h) Stretch+TGFβ induction of SMA protein expression is dependent on MRTF. Cells were transfected with NR or MRTF-specific siRNA and were subjected to 6 h of cell stretch in the presence or absence of TGFβ. Lysates were collected and analysed by western blot for the indicated proteins. Western blots in a–c,f and h are representative of a minimum of three independent experiments. Error bars in d,e and g denote ±s.e.m.; **P<0.01; ***P<0.001 by pairwise t-tests.
Figure 8 Context-dependent switch in mechanical versus mechano/chemical signalling assigns opposite role for TAZ under mechanical (single) versus mechanical+chemical (double) stimulation. (a–e) Single or double stimulation in the context of LCM-induced cell contact disassembly −/+TGFβ treatment (a) TAZ downregulation enables LCM to induce SMA expression. Cells were transfected with NR, TAZ-specific (#1) or YAP-specific siRNA for 24 h and then exposed to control or LCM medium for an additional 48 h. Cell lysates were probed for SMA and the other indicated proteins. (b) MRTF is required for the expression of SMA on TAZ downregulation and LCM treatment. Cells were transfected with NR or specific siRNAs against TAZ (#2), MRTF or their combination, and treated and analysed for the indicated proteins as in a. (c) TAZ downregulation (siTAZ #2) inhibits two-hit (LCM+TGFβ)-induced SMA protein expression. Cells were transfected with NR or TAZ siRNA followed by 48 h treatment with LCM, TGFβ or the combination. Cell lysates were subjected to western blot analysis for the indicated proteins. (d) Cells were co-transfected with the WT SMA promoter and either NR or TAZ siRNA (siTAZ #2). Luciferase activity was measured following treatment with control or LCM+TGFβ (n=3). (e) Confluent monolayers were treated with LCM or LCM+TGFβ for 24 h. ChIP analysis was performed using anti-TAZ or the relevant IgG control and primers for the SMA promoter (n=3). (f–h) Single or double stimulation in the context of stretch −/+TGFβ treatment. TAZ differentially regulates SMA expression on stimulation by stretch or by stretch and TGFβ. Cells grown on Flexcell membranes were transfected with NR or TAZ siRNA (siTAZ #1), treated without or with TGFβ and then further exposed to non-stretch or cyclic stretch conditions (10% stretch at 1 Hz for 6 h). (f) Cell lysates were prepared and analysed by western blotting for the indicated proteins. (g) The graph depicts the quantitation of SMA expression under stretch conditions. Data are expressed as fold change compared with the level of stretch+TGFβ-induced SMA expression. (h) Stretch+TGFβ induction of SMA protein expression is dependent on MRTF. Cells were transfected with NR or MRTF-specific siRNA and were subjected to 6 h of cell stretch in the presence or absence of TGFβ. Lysates were collected and analysed by western blot for the indicated proteins. Western blots in a–c,f and h are representative of a minimum of three independent experiments. Error bars in d,e and g denote ±s.e.m.; **P<0.01; ***P<0.001 by pairwise t-tests.CC BY · PubMed Central
Figure 9 Differential association between MRTF, TAZ and Smad3 on mechanical or/and TGFβ-induced stimulation. Cells were exposed to vehicle or TGFβ, followed by control (non-stretch, NS) or cyclic stretch (S) conditions for 6 h in the presence or absence of TGFβ, as in Fig. 8f. Immunoprecipitations (IPs) were performed on the resulting cell lysates using antibodies against MRTF, TAZ or Smad3, as indicated. The immunoprecipitates and input samples were then probed for the indicated proteins. The graphs show quantification of the corresponding protein–protein associations, normalized to the directly immunoprecipitated protein and using the co-precipitating protein/precipitated protein ratio obtained under non-stretch, unstimulated conditions as unity (n=3). Error bars are ±s.e.m.; **P<0.01; ***P<0.001; ****P<0.0001; ns, not significant using one-way analysis of variance.
Figure 9 Differential association between MRTF, TAZ and Smad3 on mechanical or/and TGFβ-induced stimulation. Cells were exposed to vehicle or TGFβ, followed by control (non-stretch, NS) or cyclic stretch (S) conditions for 6 h in the presence or absence of TGFβ, as in Fig. 8f. Immunoprecipitations (IPs) were performed on the resulting cell lysates using antibodies against MRTF, TAZ or Smad3, as indicated. The immunoprecipitates and input samples were then probed for the indicated proteins. The graphs show quantification of the corresponding protein–protein associations, normalized to the directly immunoprecipitated protein and using the co-precipitating protein/precipitated protein ratio obtained under non-stretch, unstimulated conditions as unity (n=3). Error bars are ±s.e.m.; **P<0.01; ***P<0.001; ****P<0.0001; ns, not significant using one-way analysis of variance.CC BY · PubMed Central
Figure 10 Interplay among MRTF, TAZ and Smad3 in the context-dependent regulation of the SMA promoter. TAZ as a switch between mechanical and mechanical/chemical signalling. Under resting conditions MRTF is inhibited by both TAZ and Smad3. On mechanical stimulation MRTF and TAZ translocate to the nucleus, but TAZ keeps MRTF in check by hindering its transport and inhibiting its transcriptional activity. Therefore, mechanical stimuli (increased substrate stiffness, stretch, loss of cell contacts and so on) will provoke only mitigated responses, which, although stimulate MRTF signalling and thereby cellular contractility, will not provoke substantial SMA expression and full-blown myofibroblast transition. This response may be critical for normal contraction of epithelial cells or fibroblasts during wound healing. This mechanism also ensures that Rho-activating mechanical stimuli do not automatically provoke a phenotype shift. If TGFβ is present along with mechanical stress, TAZ and Smad3 associate. This has a dual consequence. First, the complex becomes a potent activator of the SMA promoter, primarily through SBEs, that is, TAZ confers Smad3 sensitivity to the SMA promoter and second, while associating with each other, these factors dissociate from MRTF, thereby disinhibiting the activity of this critical mediator. These changes result in the expression of SMA (and an array of other MRTF-dependent and/or TAZ/Smad3-dependent proteins) and myofibroblast transition. This mechanism may play a key role in the pathogenesis of organ fibrosis. In addition to this basic scheme, MRTF also regulates TAZ expression, and our earlier studies suggest that TAZ controls Smad3 expression (not shown). Such pre-transcriptional and transcriptional crosstalk among these three central cytoskeleton- and TGFβ-regulated transcription factors ensure context-dependent integration of mechanical and chemical cues that, in turn, will determine the final response, which could be adaptive (healing) or maladaptive (fibrosis).
Figure 10 Interplay among MRTF, TAZ and Smad3 in the context-dependent regulation of the SMA promoter. TAZ as a switch between mechanical and mechanical/chemical signalling. Under resting conditions MRTF is inhibited by both TAZ and Smad3. On mechanical stimulation MRTF and TAZ translocate to the nucleus, but TAZ keeps MRTF in check by hindering its transport and inhibiting its transcriptional activity. Therefore, mechanical stimuli (increased substrate stiffness, stretch, loss of cell contacts and so on) will provoke only mitigated responses, which, although stimulate MRTF signalling and thereby cellular contractility, will not provoke substantial SMA expression and full-blown myofibroblast transition. This response may be critical for normal contraction of epithelial cells or fibroblasts during wound healing. This mechanism also ensures that Rho-activating mechanical stimuli do not automatically provoke a phenotype shift. If TGFβ is present along with mechanical stress, TAZ and Smad3 associate. This has a dual consequence. First, the complex becomes a potent activator of the SMA promoter, primarily through SBEs, that is, TAZ confers Smad3 sensitivity to the SMA promoter and second, while associating with each other, these factors dissociate from MRTF, thereby disinhibiting the activity of this critical mediator. These changes result in the expression of SMA (and an array of other MRTF-dependent and/or TAZ/Smad3-dependent proteins) and myofibroblast transition. This mechanism may play a key role in the pathogenesis of organ fibrosis. In addition to this basic scheme, MRTF also regulates TAZ expression, and our earlier studies suggest that TAZ controls Smad3 expression (not shown). Such pre-transcriptional and transcriptional crosstalk among these three central cytoskeleton- and TGFβ-regulated transcription factors ensure context-dependent integration of mechanical and chemical cues that, in turn, will determine the final response, which could be adaptive (healing) or maladaptive (fibrosis).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Metadata

Authors
Speight, P., Kofler, M., Szászi, K., & Kapus, A.
Affiliations
St. Michael's Hospital (CA)
Venue
Nature Communications
Published
2016-05-18
Volume
7
Issue
1
Pages
11642-11642
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2401751910
Cited by
144
References
68
Citations by year
2026: 9 · 2025: 15 · 2024: 15 · 2023: 17 · 2022: 11 · 2021: 10 · 2020: 14 · 2019: 11 · 2018: 13 · 2017: 23 · 2016: 6
FWCI
12.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Kidney Foundation of Canada
  • Canadian Institutes of Health Research (MOP- 106625)
  • Banting and Best Diabetes Centre, University of Toronto
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
MRTF, TAZ, Smad3, mechanotransduction, chemotransduction, cytoskeleton, WW domain, nuclear accumulation, TGF-beta signaling, myofibroblast differentiation, fibrogenesis, wound healing, transcriptional coactivator
MeSH terms
Actins, Animals, Swine, Transcription Factors, Transforming Growth Factor beta, LLC-PK1 Cells, Receptor Cross-Talk, Mechanotransduction, Cellular, Smad3 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.